Exagen (NASDAQ:XGN – Get Free Report) had its price objective boosted by equities research analysts at BTIG Research from $8.00 to $9.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price objective points to a potential upside of 39.53% from the stock’s current price.
Several other analysts have also commented on XGN. Roth Capital started coverage on Exagen in a report on Wednesday, June 24th. They set a “buy” rating and a $8.00 target price on the stock. Canaccord Genuity Group dropped their price target on shares of Exagen from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Weiss Ratings lowered shares of Exagen from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 12th. Finally, Wall Street Zen upgraded shares of Exagen from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.12.
Read Our Latest Analysis on XGN
Exagen Trading Up 37.8%
Exagen (NASDAQ:XGN – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06. The business had revenue of $19.94 million during the quarter, compared to analyst estimates of $17.80 million. Exagen had a negative return on equity of 94.37% and a negative net margin of 29.49%. Equities research analysts predict that Exagen will post -0.71 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in XGN. Acadian Asset Management LLC acquired a new stake in Exagen during the 1st quarter worth $25,000. Geode Capital Management LLC lifted its stake in shares of Exagen by 45.6% in the second quarter. Geode Capital Management LLC now owns 146,483 shares of the company’s stock worth $1,023,000 after buying an additional 45,884 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Exagen in the second quarter worth about $133,000. Russell Investments Group Ltd. acquired a new position in Exagen during the second quarter worth about $1,540,000. Finally, Occudo Quantitative Strategies LP acquired a new position in Exagen during the second quarter worth about $138,000. Hedge funds and other institutional investors own 75.25% of the company’s stock.
Exagen News Summary
Here are the key news stories impacting Exagen this week:
- Positive Sentiment: Exagen reported record second-quarter revenue of $19.9 million, up 16% year over year and above the $17.8 million analyst consensus. The company also reported an adjusted loss of $0.13 per share, narrower than the expected $0.19 loss. Exagen Inc. Reports Second Quarter 2026 Financial Results
- Positive Sentiment: AVISE CTD test volume increased 11%, while trailing-twelve-month average selling price rose 4% to $446 per test, indicating both demand growth and improved revenue per test. Exagen reports record Q2 revenue of $19.9 million
- Positive Sentiment: The company raised full-year 2026 revenue guidance to $72 million-$75 million, up from $70 million-$73 million and slightly above the $71.6 million consensus estimate. Exagen reports record second-quarter 2026 revenue and raises full-year guidance
- Positive Sentiment: Profitability metrics improved substantially: adjusted EBITDA loss narrowed to $0.1 million from $1.7 million a year earlier, while net loss fell nearly 30% to $3.2 million. Management said the company is approaching sustainable profitability and cash generation. Exagen Inc. Q2 2026 Earnings Call Highlights
- Neutral Sentiment: A published review involving more than 3,100 patients supported AVISE CTD’s diagnostic value, including identifying some lupus patients missed by conventional markers. This may strengthen long-term adoption, although the financial impact remains uncertain.
- Negative Sentiment: Exagen remains unprofitable, with a quarterly GAAP net loss of $3.2 million. Cash declined to approximately $24.6 million from $32.2 million at the end of 2025, while borrowings totaled roughly $22.8 million, leaving liquidity and financing needs as ongoing risks.
About Exagen
Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.
The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.
Featured Articles
- Five stocks we like better than Exagen
- Caterpillar’s Record Quarter May Have Reset the Stock’s Ceiling
- The Real Reason Amazon Hit a $3 Trillion Valuation
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.
